The global pharmaceutical industry experienced a 24% rise in the number of Covid-19-related patent applications in Q2 2023 compared with the previous quarter. The total number of Covid-19-related grants rose by 93% in Q2 2023, according to GlobalData’s Patent Analytics. GlobalData’s COVID-19 Cross-Sector Impact – Thematic Research report helps understand how the effect of COVID-19 on pharmaceutical sector compares with 17 other key sectors, in terms of equity indices, M&A volumes, jobs index, and filings. Buy the report here.
Notably, the number of Covid-19-related patent applications in the pharmaceutical industry was 663 in Q2 2023, versus 536 in the prior quarter.
The top five companies accounted for 4% of patenting activity
Analysis of patenting activity by companies shows that F. Hoffmann-La Roche filed the most Covid-19 patents within the pharmaceutical industry in Q2 2023. The company filed 7 Covid-19-related patents in the quarter, compared with 2 in the previous quarter. It was followed by Tsinghua University with 6 Covid-19 patent filings, Enanta Pharmaceuticals (5 filings), and Shanghai Institute of Materia Medica Chinese Academy of Sciences (4 filings) in Q2 2023.
Patenting activity was driven by the US with a 44% share of total patent filings
The largest share of Covid-19 related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 44%, followed by China (10%) and Japan (8%). The share represented by the US was 35% higher than the 9% share it accounted for in Q1 2023.
To further understand GlobalData's analysis on COVID-19 Cross-Sector Impact - Thematic Research buy the report here.